Endocrinology CME Courses
Endocrinology CME Courses
Keep Up with Current Trends in Your Field
This CME course in endocrinology is extremely thorough, covering a range of key topics and core concepts in the specialty aiming to facilitate correct diagnosis and treatment of endocrine disorders. The Brigham Board Review in Endocrinology includes case-based lectures on topics like type 1 and type 2 diabetes, thyroid cancers, pituitary masses, polycystic ovarian syndrome, infertility and assisted reproduction, obesity management, etc. It will help you to better:
- Prepare for ABIM Endocrinology certification and recertification examinations
- Integrate and demonstrate increased overall knowledge of endocrine diseases
- Correlate pathophysiology and pathobiology with clinical presentations
- Evaluate the current therapeutic strategies with risks and potential benefits
- Attain the latest knowledge for managing diabetes, endocrine hypertension, hypothyroidism, etc.
- Apply knowledge attained to your daily practice, optimizing patient care and outcomes
Speakers:
Matthew H. Kulke, MD, MMSc, Associate Professor of Medicine, Director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School
David C. Metz, MBBCh, is Professor of Medicine at the Perelman School of Medicine (University of Pennsylvania)
Topic and Learning Objectives
- To incorporate evidence-based practices into the management of carcinoid syndrome
- Review the efficacy and safety of treatment programs for carcinoid syndrome
- To summarize the causes of carcinoid syndrome
- Review the differential diagnosis and appropriate workup for the presenting symptoms
This activity is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome. Considering the symptoms and potential complications involved in carcinoid syndrome, clinicians in cardiology, dermatology, pulmonary medicine, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.
By the end of the session the participant will be able to:
- Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
- Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
- Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
- Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case
By the end of the session the participant will be able to:
- Describe the underlying pathophysiological and typical clinical features of pediatric GHD as they pertain to therapeutic targets
- Describe the optimal approach in diagnosing pediatric GHD and apply it to a patient case
- Given a patient with pediatric GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation
- Evaluate patient cases during follow-up visits, including during transition therapy to adulthood when relevant, in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence
- Describe best practices in tracking response to pediatric GHD therapy
By the end of the session the participant will be able to:
- Apply existing guideline recommendations in the diagnosis of HCC
- Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
- Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
- Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case